{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytarabine+intravenous", "query": { "intervention": "Cytarabine intravenous" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 121, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytarabine+intravenous&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T10:04:56.584Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00928200", "title": "Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Acute Lymphoblastic Leukemia", "Allergy to PEG e.Coli Asparaginase", "Allergy to Native e.Coli Asparaginase" ], "interventions": [ { "name": "Erwinase", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Triple Intrathecal Therapy", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 1, "start_date": "2009-04-13", "completion_date": "2010-06-04", "has_results": true, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-09-25T10:04:56.584Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00928200" }, { "nct_id": "NCT05735184", "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Mixed Lineage Leukemia Gene Mutation", "Refractory AML", "AML With Mutated NPM1", "Acute Myeloid Leukemia Recurrent", "Acute Myeloid Leukemia, in Relapse", "NPM1 Mutation", "KMT2Ar", "Myeloid Sarcoma", "Nucleophosmin 1-mutated Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Quizartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2023-07-18", "completion_date": "2030-04", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-09-25T10:04:56.584Z", "location_count": 44, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05735184" }, { "nct_id": "NCT00778375", "title": "Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 122, "start_date": "2008-10", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-09-25T10:04:56.584Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00778375" }, { "nct_id": "NCT00000689", "title": "Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "HIV Infections" ], "interventions": [ { "name": "Bleomycin sulfate", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Leucovorin calcium", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 18, "start_date": null, "completion_date": "1991-03", "has_results": false, "last_update_posted_date": "2021-11-02", "last_synced_at": "2026-09-25T10:04:56.584Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000689" }, { "nct_id": "NCT03459859", "title": "Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "AML", "Advanced Myelodysplastic Syndromes", "MDS" ], "interventions": [ { "name": "Pevonedistat", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Justin Watts, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2018-05-21", "completion_date": "2021-06-25", "has_results": false, "last_update_posted_date": "2021-12-28", "last_synced_at": "2026-09-25T10:04:56.584Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03459859" }, { "nct_id": "NCT01130194", "title": "Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Combination of treatment modalities", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "St. Louis University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 29, "start_date": "2006-07", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2014-05-12", "last_synced_at": "2026-09-25T10:04:56.584Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01130194" }, { "nct_id": "NCT04047641", "title": "Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Blasts 20 Percent or More of Bone Marrow Nucleated Cells", "High Risk Myelodysplastic Syndrome", "Recurrent Acute Biphenotypic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent High Risk Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory High Risk Myelodysplastic Syndrome" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Quizartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2019-10-22", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-25T10:04:56.584Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04047641" }, { "nct_id": "NCT01721876", "title": "Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Volasertib", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 666, "start_date": "2013-01-29", "completion_date": "2021-05-28", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-09-25T10:04:56.584Z", "location_count": 4, "location_summary": "Los Angeles, California • Duluth, Minnesota • Nashville, Tennessee + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Duluth", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721876" }, { "nct_id": "NCT01773408", "title": "A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelogenous Leukemia, Acute" ], "interventions": [ { "name": "RO5503781 MBP", "type": "DRUG" }, { "name": "RO5503781 SDP", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2013-02", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2017-01-25", "last_synced_at": "2026-09-25T10:04:56.584Z", "location_count": 4, "location_summary": "Los Angeles, California • Valhalla, New York • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Valhalla", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01773408" }, { "nct_id": "NCT00536978", "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Leukemia" ], "interventions": [ { "name": "ARA-C", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Campath-1H", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Allogeneic Stem Cell Transplantation", "type": "OTHER" }, { "name": "Total body radiation (TBI)", "type": "RADIATION" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Adback NK or T Cell", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 22, "start_date": "2007-09", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-09-25T10:04:56.584Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00536978" } ] }